About Us

Contact us
Community Advisory Board
Readers Rep
Careers
Events
Historical Archives
Recent Quotes
My Watchlist
Indicators
Local Stocks
San Diego Stocks
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Genentech

< Previous 1 2 3 4 5 Next >
News headline image
Genentech’s Fenebrutinib Maintains Near-Complete Suppression of Disease Activity and Disability Progression for up to Two Years in People With Relapsing Multiple Sclerosis
From Genentech
Via Business Wire
Tickers RHHBY
News headline image
New Two-year Follow-up of Genentech’s Columvi Extends Overall Survival in Relapsed or Refractory Diffuse Large B-cell Lymphoma Patients
From Genentech
Via Business Wire
Tickers RHHBY
News headline image
FDA Approves Genentech’s Susvimo for Diabetic Retinopathy
From Genentech
Via Business Wire
Tickers RHHBY
News headline image
Genentech Provides Update on FDA Advisory Committee Meeting on Columvi Combination for People With Relapsed or Refractory Diffuse Large B-cell Lymphoma
From Genentech
Via Business Wire
Tickers RHHBY
News headline image
Ten-Year APHINITY Data Show Genentech’s Perjeta-based Regimen Reduced the Risk of Death by 17% in HER2-Positive Early-Stage Breast Cancer
From Genentech
Via Business Wire
Tickers RHHBY
News headline image
Roche and Genentech Announce New North Carolina Manufacturing Facility
From Genentech
Via Business Wire
Tickers RHHBY
News headline image
New England Journal of Medicine Publishes Phase III Data Showing Single-dose Xofluza Significantly Reduces Influenza Virus Transmission
From Genentech
Via Business Wire
Tickers RHHBY
News headline image
Genentech and Roche Present Novel Therapeutic and Diagnostic Advancements in Alzheimer’s at AD/PD 2025
From Genentech
Via Business Wire
Tickers RHHBY
News headline image
Genentech Provides Update on Phase III Ocrevus High Dose Study in People With Relapsing Multiple Sclerosis
From Genentech
Via Business Wire
Tickers RHHBY
News headline image
FDA Accepts Supplemental Biologics License Application for Genentech’s Gazyva for the Treatment of Lupus Nephritis
From Genentech
Via Business Wire
Tickers RHHBY
News headline image
FDA Approves Genentech’s TNKase® in Acute Ischemic Stroke in Adults
From Genentech
Via Business Wire
Tickers RHHBY
News headline image
Phase III Study Shows Xolair May Be More Effective With Fewer Side Effects Than Oral Immunotherapy for the Treatment of Food Allergies
From Genentech
Via Business Wire
Tickers RHHBY
News headline image
FDA Approves Genentech’s Evrysdi Tablet as First and Only Tablet for Spinal Muscular Atrophy (SMA)
From Genentech
Via Business Wire
Tickers RHHBY
News headline image
New England Journal of Medicine Publishes New Data for Genentech’s Gazyva Which Shows Superiority Over Standard Therapy in People With Active Lupus Nephritis
From Genentech
Via Business Wire
Tickers RHHBY
News headline image
FDA Approves Genentech’s Susvimo as the First and Only Continuous Delivery Treatment for the Leading Cause of Diabetes-Related Blindness
From Genentech
Via Business Wire
Tickers RHHBY
News headline image
Genentech’s Itovebi Demonstrated Statistically Significant and Clinically Meaningful Overall Survival Benefit in a Certain Type of HR-Positive Advanced Breast Cancer
From Genentech
Via Business Wire
Tickers RHHBY
News headline image
Genentech’s Phase IIb Study of Prasinezumab Missed Primary Endpoint, but Suggests Possible Benefit in Early-Stage Parkinson’s Disease
From Genentech
Via Business Wire
Tickers RHHBY
News headline image
New and Updated Data for Genentech’s Fixed-Duration Columvi and Lunsumio at ASH 2024 Reinforce Their Potential to Improve Outcomes for People With Lymphoma
From Genentech
Via Business Wire
Tickers RHHBY
News headline image
Five-Year Results Confirm Genentech’s Polivy Combination Therapy as New Standard of Care for Previously Untreated Aggressive Lymphoma
From Genentech
Via Business Wire
Tickers RHHBY
News headline image
FDA Accepts Supplemental Biologics License Application for Genentech’s Columvi Combination for People With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
From Genentech
Via Business Wire
Tickers RHHBY
News headline image
Genentech Reports Update on Phase III SKYSCRAPER-01 Study Results
From Genentech
Via Business Wire
Tickers RHHBY
News headline image
Genentech to Present New and Encouraging Long-term Follow-up Data Across Broad Hematology Portfolio at ASH 2024
From Genentech
Via Business Wire
Tickers RHHBY
News headline image
New England Journal of Medicine Publishes Landmark Phase III Results for Genentech’s Itovebi, Showing More Than Doubling of Progression-Free Survival in Certain Type of HR-Positive Advanced Breast Cancer
From Genentech
Via Business Wire
Tickers RHHBY
News headline image
Genentech’s Vabysmo Improved Vision in Underrepresented Populations With Diabetic Macular Edema (DME) in a First-Of-Its-Kind Study
From Genentech
Via Business Wire
Tickers RHHBY
News headline image
Majority of Children With Spinal Muscular Atrophy (SMA) Treated With Genentech’s Evrysdi Are Able to Sit, Stand and Walk Independently, Two-Year Data Demonstrate
From Genentech
Via Business Wire
Tickers RHHBY
News headline image
FDA Approves Genentech’s Itovebi, a Targeted Treatment for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer With a PIK3CA Mutation
From Genentech
Via Business Wire
Tickers RHHBY
News headline image
Positive Phase III Results for Genentech’s Gazyva Show Superiority to Standard Therapy Alone in People With Lupus Nephritis
From Genentech
Via Business Wire
Tickers RHHBY
News headline image
Positive Phase III Results Show Xofluza Significantly Reduces the Transmission of Influenza Viruses
From Genentech
Via Business Wire
Tickers RHHBY
News headline image
FDA Approves Ocrevus Zunovo™ as the First and Only Twice-a-Year 10-Minute Subcutaneous Injection for People With Relapsing and Progressive Multiple Sclerosis
From Genentech
Via Business Wire
Tickers RHHBY
News headline image
FDA Approves Genentech’s Tecentriq Hybreza, the First and Only Subcutaneous Anti-PD-(L)1 Cancer Immunotherapy
From Genentech
Via Business Wire
Tickers RHHBY
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.